

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

HCC1395

RRID:CVCL_1249

Type: Cell Line

Proper Citation

RRID:CVCL_1249

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1249

Proper Citation: RRID:CVCL_1249

Description: Cell line HCC1395 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast ductal carcinoma

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12800145](#), [PMID:14762065](#), [PMID:16959974](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28287265](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1395

Synonyms: HCC-1395, SCC-1395, Hamon Cancer Center 1395

Cross References: BTO:BTO_0003444, CLO:CLO_0003634, EFO:EFO_0002185, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2324, BioGRID_ORCS_Cell_line:428, BioSample:SAMN03471290, BioSample:SAMN03471814, BioSample:SAMN10987926, cancercellines:CVCL_1249, Cell_Model_Passport:SIDM00884, ChEMBL-Cells:ChEMBL3308106, ChEMBL-Targets:ChEMBL1075454, CLS:305546, Cosmic:749712, Cosmic:904362, Cosmic:1047707, Cosmic:1235081, Cosmic:1287935, Cosmic:1309005, Cosmic:1430349, Cosmic:1460232, Cosmic:1473080, Cosmic:1518111, Cosmic:1603200, Cosmic:1935004, Cosmic:2164990, Cosmic-CLP:749712, DepMap:ACH-000699, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:749712, GEO:GSM186714, GEO:GSM186715, GEO:GSM217572, GEO:GSM219969, GEO:GSM302884, GEO:GSM302885, GEO:GSM302886, GEO:GSM302887, GEO:GSM302888, GEO:GSM302889, GEO:GSM302890, GEO:GSM302891, GEO:GSM302892, GEO:GSM302893, GEO:GSM302894, GEO:GSM344377, GEO:GSM344427, GEO:GSM350539, GEO:GSM481302, GEO:GSM533401, GEO:GSM533408, GEO:GSM537971, GEO:GSM783934, GEO:GSM844543, GEO:GSM847321, GEO:GSM887037, GEO:GSM888107, GEO:GSM1008897, GEO:GSM1053698, GEO:GSM1172863, GEO:GSM1172957, GEO:GSM1214582, GEO:GSM1374496, GEO:GSM1374497, GEO:GSM1669843, IARC_TP53:10271, IGRhCellID:HCC1395, KCLB:9S1395, LiGeA:CCLE_314, LINCS_HMS:50206, LINCS_LDP:LCL-1330, PharmacDB:HCC1395_473_2019, PRIDE:PXD005295, PRIDE:PXD030304, Progenetix:CVCL_1249, PubChem_Cell_line:CVCL_1249, SLKBase:3511, Wikidata:Q54881565

ID: CVCL_1249

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260905T180217+0000

Ratings and Alerts

No rating or validation information has been found for HCC1395.

No alerts have been found for HCC1395.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 147 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates.

The Journal of biological chemistry, 302(4), 111302.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer. Apoptosis : an international journal on programmed cell death, 31(5).

Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. bioRxiv : the preprint server for biology.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Dibra D, et al. (2024) Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Science advances, 10(7), eadk1835.

Beniey M, et al. (2023) Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. British journal of cancer, 128(10), 1964.

Cotto KC, et al. (2023) Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. Nature communications, 14(1), 1589.

Schröfelbauer B, et al. (2023) Discovery of antibodies and cognate surface targets for ovarian cancer by surface profiling. Proceedings of the National Academy of Sciences of the United States of America, 120(1), e2206751120.

Xie X, et al. (2023) Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. Biomedicines, 11(3).

Heesch A, et al. (2023) The Potential of PSMA as a Vascular Target in TNBC. Cells, 12(4).

Sun Y, et al. (2023) RAD21 is the core subunit of the cohesin complex involved in directing genome organization. Genome biology, 24(1), 155.

Stefanski CD, et al. (2023) APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. International journal of molecular sciences, 24(8).

Li Y, et al. (2023) PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition. Cell reports. Medicine, 4(12), 101326.

Chen K, et al. (2023) Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer cell, 41(10), 1749.

Jovanović B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. Cell reports, 42(12), 113564.

Kim H, et al. (2023) Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. *Cell reports*, 42(10), 113256.

Feng Y, et al. (2023) Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. *Cell reports*, 42(12), 113503.

Adams CM, et al. (2023) Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer. *Cancer discovery*, 13(5), 1210.

Koval A, et al. (2023) Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells. *iScience*, 26(8), 107270.